Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer.


Journal

American journal of nephrology
ISSN: 1421-9670
Titre abrégé: Am J Nephrol
Pays: Switzerland
ID NLM: 8109361

Informations de publication

Date de publication:
2022
Historique:
received: 28 07 2022
accepted: 22 09 2022
pubmed: 22 12 2022
medline: 27 1 2023
entrez: 21 12 2022
Statut: ppublish

Résumé

We examined the association of proteinuria with the risk for heart failure (HF) and other cardiovascular disease (CVD) events in patients with prior history of breast, colorectal, or stomach cancer using a nationwide population-based database. We conducted this retrospective observation study using the JMDC Claims Database and analyzed 55,191 patients with prior history of breast, colorectal, or stomach cancer. The median age was 54 (48-60) years, and 20,665 participants (37.4%) were men. Using urine dipstick data at baseline, 3,945 and 1,521 participants were categorized as having trace and positive proteinuria, respectively. Using Cox proportional hazards models, we examined the relationship of proteinuria with the incidence of HF and other CVD events. Over a mean follow-up of 2.8 ± 2.2 years, 1,597 HF, 124 myocardial infarction, 1,342 angina pectoris, 719 stroke, and 361 atrial fibrillation events were recorded. Kaplan-Meier curves showed that the cumulative incidence for HF increased with proteinuria category (log-rank p < 0.001). After multivariable adjustment, hazard ratios of trace and positive proteinuria for HF were 1.24 (95% CI, 1.04-1.47) and 1.62 (95% CI, 1.30-2.02), respectively. The presence of proteinuria was also associated with a higher risk for angina pectoris and atrial fibrillation. Proteinuria was associated with a greater risk of developing HF and other CVD events in patients with prior history of cancer. The optimal management strategy for patients with proteinuria and cancer needs to be established for the prevention of HF in cancer patients.

Identifiants

pubmed: 36543162
pii: 000527703
doi: 10.1159/000527703
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

753-760

Informations de copyright

© 2022 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Yuta Suzuki (Y)

The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.

Hidehiro Kaneko (H)

The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
The Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan.

Akira Okada (A)

Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Katsuhito Fujiu (K)

The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
The Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan.

Nobuaki Michihata (N)

The Department of Health Services Research, The University of Tokyo, Tokyo, Japan.

Taisuke Jo (T)

The Department of Health Services Research, The University of Tokyo, Tokyo, Japan.

Norifumi Takeda (N)

The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.

Hiroyuki Morita (H)

The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.

Kentaro Kamiya (K)

Department of Rehabilitation, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan.

Atsuhiko Matsunaga (A)

Department of Rehabilitation, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan.

Junya Ako (J)

Department of Cardiovascular Medicine, Kitasato University School of Medicine, Kanagawa, Japan.

Koichi Node (K)

Department of Cardiovascular Medicine, Saga University, Saga, Japan.

Masaomi Nangaku (M)

Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Hideo Yasunaga (H)

The Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.

Issei Komuro (I)

The Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH